Gunter A.
- Country
- Germany
- Department
- Klinik fuer Rheumatologie und Klinische Immunologie
Research Overview
- Evaluation of CNTY-101, a CD19-targeted CAR iNK Cell Therapy, in Refractory Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, and Diffuse Cutaneous Systemic Sclerosis
- Long-Term Follow-up Study of Century Therapeutics Cellular Therapy in Hematological Malignancies, Solid Tumors, and Autoimmune Diseases
- A Phase 3 Randomized Controlled Trial to Evaluate the Efficacy and Safety of Rilzabrutinib in Adults with Active IgG4-Related Disease
Data & Insights
Has run more than one trial at 131 of 308 partner sites.
Specializations
Rheumatic and Autoimmune Conditions
The investigator specializes in treating complex systemic autoimmune disorders, with particular focus on systemic lupus erythematosus and systemic sclerosis. Their research encompasses innovative therapeutic approaches for managing these chronic conditions.
- Systemic Lupus Erythematosus (SLE)
- Giant Cell Arteritis
- Psoriatic Arthritis
Pulmonary Complications
Their expertise extends to the treatment of interstitial lung diseases, particularly those associated with connective tissue disorders. The investigator focuses on developing therapeutic strategies for managing respiratory manifestations in autoimmune conditions.
- Interstitial Lung Disease (ILD)
- Bronchial Diseases
- Systemic Sclerosis-Associated ILD
Specialized Therapeutic Areas
The investigator works with advanced treatments for inflammatory conditions, including novel biological therapies and targeted immunological interventions. Their research includes the evaluation of cell-based therapies for autoimmune diseases.
- Eosinophilic Granulomatosis with Polyangiitis
- B Cell-Mediated Autoimmune Diseases
- Systemic Autoimmune Rheumatic Diseases
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.